Table 3.
Baseline characteristicsa)
| Variable | JMII PCb/P (n=109) | S110 PC/P ind+mnt (n=27) | S110 PC/P mnt (n=22) | PARAMOUNT P+BSC mnt (n=359) |
|---|---|---|---|---|
| Age (yr) | ||||
| Median (range) | 63 (38-78) | 57.0 (29-75) | 54.5 (29-74) | 61 (32-79) |
| Gender | ||||
| Female | 40 (36.7) | 22 (81.5) | 17 (77.3) | 158 (44) |
| Male | 69 (63.3) | 5 (18.5) | 5 (22.7) | 201 (56) |
| Ethnic origin | ||||
| Asian | - | - | - | 16 (4) |
| Japan | 109 (100) | - | - | - |
| China | - | 13 (48.1) | 12 (54.5) | - |
| Korea | - | 6 (22.2) | 5 (22.7) | - |
| Taiwan | - | 8 (29.6) | 5 (22.7) | - |
| Caucasian | - | - | - | 339 (94) |
| African | - | - | - | 4 (1) |
| Stage of disease | ||||
| Stage IIIB | 33 (30.3) | 3(11.1) | 3 (13.6) | 31 (9) |
| Stage IV | 72 (66.1) | 24 (88.9) | 19 (86.4) | 328 (91) |
| Recurrence | 4 (3.7) | - | - | - |
| ECOG performance status | ||||
| 0 | 37 (33.9) | 8 (29.6) | 8 (36.4) | 115 (32) |
| 1 | 72 (66.1) | 19 (70.4) | 14 (63.6) | 243 (68) |
| 2-3 | - | - | - | 1 ( < 1) |
| Histological subtypes | ||||
| Adenocarcinoma | 106 (97.2)b) | 24 (88.9) | 21 (95.5) | 304 (85) |
| Large cell | 3 (2.8) | 1 (3.7) | - | 24 (7) |
| Bronchoalveolar | - | - | - | 6 (2) |
| Other | - | 2 (7.4) | 1 (4.5) | 25 (7) |
| Smoking | ||||
| Ever | 76 (69.7) | 2 (7.4) | 1 (4.5) | 275 (77) |
| Never | 33 (30.3) | 25 (92.6) | 21 (95.5) | 82 (23) |
| Unknown | 0 | 0 | - | 2 ( < 1) |
| EGFR mutation status | ||||
| Positive | 24 (22.0) | - | - | - |
| Negative | 63 (57.8) | - | - | - |
| Unknown | 3 (2.8) | - | - | - |
| Not done | 19 (17.4) | - | - | - |
Values are presented as number (%). PCb/P, pemetrexed+carboplatin followed by pemetrexed; PC/P, pemetrexed+cisplatin followed by pemetrexed; ind, induction; mnt, maintenance; P+BSC, pemetrexed+best supportive care; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer.
a)
Baseline characteristics prior to induction for studies JMII and S110, but prior to maintenance for PARAMOUNT randomization,
b)
Includes 1 patient reclassified as having squamous NSCLC after study entry and examination of EGFR gene type was not done.